Quick Answer
Cartesian Therapeutics, Inc. reported R&D Expense of $58.03 million for fiscal year 2025.
Cartesian Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $58.03M | +28.7% |
| 2024 | $45.10M | -36.7% |
| 2023 | $71.26M | -1.5% |
| 2022 | $72.38M | +5.3% |
| 2021 | $68.74M | +26.1% |
| 2020 | $54.51M | +27.5% |
| 2019 | $42.74M | -10.4% |
| 2018 | $47.69M | +5.6% |
| 2017 | $45.16M | +52.1% |
| 2016 | $29.70M | +29.3% |
| 2015 | $22.98M | +119.1% |
| 2014 | $10.49M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.80M | +21.1% | -7.2% |
| June 30, 2025 | $14.87M | +17.4% | +1.3% |
| March 31, 2025 | $14.67M | +50.7% | +28.7% |
| September 30, 2024 | $11.40M | -12.3% | -10.0% |
| June 30, 2024 | $12.66M | -28.8% | +30.0% |
| March 31, 2024 | $9.74M | -47.7% | -25.1% |
| September 30, 2023 | $13.00M | -21.4% | -26.9% |
| June 30, 2023 | $17.78M | -7.3% | -4.5% |
- Cartesian Therapeutics, Inc. showed an increase of +28.7% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Cartesian Therapeutics, Inc.’s r&d expense has grown by 453.4% (from $10.49 million to $58.03 million).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: